MY120461A - Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia. - Google Patents

Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia.

Info

Publication number
MY120461A
MY120461A MYPI98005180A MYPI9805180A MY120461A MY 120461 A MY120461 A MY 120461A MY PI98005180 A MYPI98005180 A MY PI98005180A MY PI9805180 A MYPI9805180 A MY PI9805180A MY 120461 A MY120461 A MY 120461A
Authority
MY
Malaysia
Prior art keywords
alkyl
alkoxycarbonyl
mono
halogen
amino
Prior art date
Application number
MYPI98005180A
Other languages
English (en)
Inventor
Maffrand Jean-Pierrre
Soubrie Philippe
Terranova Jean-Paul
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY120461A publication Critical patent/MY120461A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI98005180A 1997-11-14 1998-11-14 Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia. MY120461A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
MY120461A true MY120461A (en) 2005-10-31

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98005180A MY120461A (en) 1997-11-14 1998-11-14 Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia.

Country Status (27)

Country Link
EP (1) EP1030671A1 (is)
JP (1) JP2001523642A (is)
KR (1) KR100599350B1 (is)
CN (1) CN1243540C (is)
AU (1) AU743228B2 (is)
BG (1) BG64819B1 (is)
BR (1) BR9814035A (is)
CA (1) CA2309966A1 (is)
CO (1) CO4980891A1 (is)
DZ (1) DZ2649A1 (is)
EA (1) EA003255B1 (is)
EE (1) EE04235B1 (is)
HU (1) HUP0100098A3 (is)
ID (1) ID24933A (is)
IL (2) IL136122A0 (is)
IS (1) IS5482A (is)
MY (1) MY120461A (is)
NO (1) NO20002450L (is)
NZ (1) NZ504420A (is)
OA (1) OA11464A (is)
PL (1) PL194597B1 (is)
SA (1) SA98190747B1 (is)
SK (1) SK286040B6 (is)
TR (1) TR200001262T2 (is)
TW (1) TW585766B (is)
UY (1) UY25247A1 (is)
WO (1) WO1999025363A1 (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
JP2005534710A (ja) * 2002-08-07 2005-11-17 ノバルティス アクチエンゲゼルシャフト Ａｐｏｅ遺伝子型を基準とした痴呆を処置するための方法
CN1520818A (zh) * 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
ES2244968T3 (es) * 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
CN1285742A (zh) 2001-02-28
EP1030671A1 (fr) 2000-08-30
DZ2649A1 (fr) 2004-12-28
BR9814035A (pt) 2000-09-26
TW585766B (en) 2004-05-01
CA2309966A1 (en) 1999-05-27
BG64819B1 (bg) 2006-05-31
UY25247A1 (es) 2001-05-31
EE200000290A (et) 2001-06-15
AU1160999A (en) 1999-06-07
KR100599350B1 (ko) 2006-07-12
OA11464A (en) 2003-11-18
CO4980891A1 (es) 2000-11-27
NZ504420A (en) 2003-08-29
PL194597B1 (pl) 2007-06-29
SK286040B6 (sk) 2008-01-07
IL136122A (en) 2006-07-05
EA200000412A1 (ru) 2000-12-25
KR20010032099A (ko) 2001-04-16
NO20002450D0 (no) 2000-05-11
JP2001523642A (ja) 2001-11-27
EA003255B1 (ru) 2003-02-27
SA98190747B1 (ar) 2006-11-04
CN1243540C (zh) 2006-03-01
BG104428A (en) 2001-08-31
TR200001262T2 (tr) 2001-01-22
IS5482A (is) 2000-05-09
SK7112000A3 (en) 2000-10-09
EE04235B1 (et) 2004-02-16
HUP0100098A2 (hu) 2001-07-30
IL136122A0 (en) 2001-05-20
NO20002450L (no) 2000-07-14
PL340500A1 (en) 2001-02-12
WO1999025363A1 (fr) 1999-05-27
ID24933A (id) 2000-08-31
HUP0100098A3 (en) 2001-12-28
AU743228B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
CA2225746A1 (en) 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridines having neurotrophic and neuroprotective activity
HUT60733A (en) Process for producing new n-(4-piperidinyl)-(dihydrobenzofuran or dihydro-2h-benzopyran)-carboxamide derivatives and pharmaceutical compositions comprising such compounds
MY120461A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia.
TW429244B (en) Arylsulfonamido-substituted hydroxamic acids
AU2003278296A1 (en) Piperidine quinolyl propyl derivatives, preparation method and intermediates and compositions containing same
EP0300882A3 (en) Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
NZ336033A (en) 4-substituted 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease
IL116387A0 (en) Use of 5-acyl-1,4-dihydropyridines
JP2001523642A5 (is)
WO1995010188A3 (en) Herbicidal aza bisphosphonic acid compositions
AR013750A1 (es) Asociacion de principios activos para el tratamiento de la demencia senil de tipo alzheimer
HUP0001181A2 (hu) Mikrorészecske formájú tetrahidropiridinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények